NZ728110B2 - Solid oral dosage form of lipophilic compounds - Google Patents

Solid oral dosage form of lipophilic compounds Download PDF

Info

Publication number
NZ728110B2
NZ728110B2 NZ728110A NZ72811015A NZ728110B2 NZ 728110 B2 NZ728110 B2 NZ 728110B2 NZ 728110 A NZ728110 A NZ 728110A NZ 72811015 A NZ72811015 A NZ 72811015A NZ 728110 B2 NZ728110 B2 NZ 728110B2
Authority
NZ
New Zealand
Prior art keywords
composition
oil
fatty acids
long chain
chain fatty
Prior art date
Application number
NZ728110A
Other versions
NZ728110A (en
Inventor
Jgaard Bent H
Original Assignee
Pebean Pharma Aps
Filing date
Publication date
Application filed by Pebean Pharma Aps filed Critical Pebean Pharma Aps
Priority claimed from PCT/EP2015/063606 external-priority patent/WO2015193380A2/en
Publication of NZ728110A publication Critical patent/NZ728110A/en
Publication of NZ728110B2 publication Critical patent/NZ728110B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/20—Agglomerating; Granulating; Tabletting
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/20—Agglomerating; Granulating; Tabletting
    • A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A23P10/35—Encapsulation of particles, e.g. foodstuff additives with oils, lipids, monoglycerides or diglycerides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention relates to a self-emulsifying pharmaceutical composition comprising compound having a log P of at least 5 and a vehicle, wherein the vehicle comprises (a) a fat component in an amount sufficient to achieve lymphatic absorption in a mammal, selected from mono- and tri-glycerides of long chain fatty acids in a weight ratio of 2.8:1 to 1:5, and (b) a hydrophilic surfactant, wherein (a):(b) is in a weight ratio of 10:1 to 1:2. The composition is useful for administering a lipophilic compound to fasted or fed mammals.

Description

TITLE: SOLID ORAL DOSAGE FORM OF LIPOPHILIC COMPOUNDS FIELD OF THE INVENTION This invention relates to a ition comprising a self—emulsifying drug delivery system capable of delivering and controlling the uptake of compounds having a log P of at least 5 through the lymph and ed for oral use.
The invention provides a mean for controlling the uptake of such compounds improving the absorption and at the same time reducing the variability in the absorption thereby having the advantage that it can be taken both in fed and in fasted state with a reduced or an e of food effect on the uptake of the compound.
The self-emulsifying drug delivery system can optionally be formulated into a solid oral dosage form ?irther modifying the release thereby leading to a better uptake through the lymph compared to prior oral solid dosage forms of said compounds. The invention provides a composition of a solid oral dosage form containing the self-emulsifying drug delivery system. The self—emulsifying drug delivery system can be included partly in the tablet core to improve the compressibility of said tablet.
The invention relates to pharmaceutical products as well as to dietary supplements.
BACKGROUND OF THE INVENTION While solid oral dosage forms (granules, tablets or capsules etc.) ent the most convenient and e route of stration, it is also a fact that many compounds have very poor and variable oral absorption characteristics. This makes the oral administration of these compounds unsuitable for getting plasma levels high enough to be therapeutically active, or plasma levels stable enough to be within the therapeutic window to maintain therapeutic effect and to avoid toxic peak . Absorption problems are normally classi?ed as either due to very low solubility or low permeability. Low solubility causes the compounds to pass through the gastrointestinal tract (GI tract) without being dissolved and therefore not being absorbed. bility problems occur, where the compound is soluble, but is not absorbed suf?ciently to give any signi?cant blood . Such permeability problems can be due to a variety of factors most commonly (l) metabolic ility in the GI tract (2) extensive metabolism when passing the GI barrier (typical CYP metabolism) (3) ?rst pass metabolism from portal vein passing the liver and (4) substrate for the P—glycoprotein (P-gp) ef?ux pump in the GI tract.
Peptides are an example of a class of les that typically show poor oral absorption due to extensive metabolism in the GI tract primarily due to enzymatic ation in the stomach and upper intestines.
Paclitaxel is another example of compound having bility issues. Paclitaxel is a taxane used for treatment of oncology indications like breast cancer and ovarian cancer and having a log P of 3.6.
Currently Paclitaxel is only ble for intravenous infusion due to a very low and variable oral absorption unable to provide therapeutic relevant drug concentrations. Paclitaxel is a molecule with very low lity (<0.05 mg/ml). CYP3A4 metabolism in the intestine and liver, as well as P—gp mediated ef?ux activity, are important hindrances for oral absorption of paclitaxel as also described by Kruij er et al. (The Oncologist 7, 516-530, 2002) and long 800 Woo et al (Pharm. Res. 20, 24-30, 2003) ).
Yet another example is the enous drug propofol that due to excessive ?rst pass metabolism has an oral ilability of only 3% or lower. Propofol (2,6-diisopropylphenol) is the most extensively used general etic—sedative agent employed today but its use is limited to intravenous dosing necessitating only hospital use. However, Propofol has a long range of pharmacological ties that could be better utilized if an oral dosage form could be made suf?ciently bioavailable. Propofol is a potent antioxidant and has been shown to stimulate protein kinase C, inhibit calcium entry in muscle cells and increase the calcium sensitivity of myo?laments in ventricular myocytes. Propofol is also a potent direct vasodilator and bronchodilator and possess anti-in?ammatory and antiseizure properties.
The lymphatic path is an alternate pathway to oral tion by which highly lipophilic compounds can access systemic circulation by uptake in the chylomicrons secreted by the small intestines and thereby be transported in the lymph. In addition this path has the advantage of avoidance of c ?rst-pass metabolism.
Lymphatic absorption is a complex s which is in?uenced by the formulation as well as by the food taken at the time of dosing. In literature it is described that lipophilic compounds with high log P values can be ed into the enterocytes and be orated into lipoproteins inside the enterocytes. The compound has to dissolve in the GI—tract and pass the unstirred water layer prior to absorption into the enterocytes. To achieve this, drugs can "hide" in micelles formed either from lipid digestion products and bile or from surfactants present in the formulation.
Fatty acids and monoglycerides are taken up at the same time and re—synthesized to triglycerides, which forms the center of the lipoproteins. Those lipoproteins are then osed from the enterocytes into the lumen and have to diffuse to the lymph. This transport of compound can be increased by increasing the ?ow of lipoproteins, which again will depend on the amount of lipids in the gut.
As fatty acids and monoglycerides are critical to this absorption mechanism, they have to be supplied either from food or from the formulation of the compound. This can be in the form of fats, triglycerides, monoglycerides or fatty acids. Fats need to be digested to fatty acids and monoglycerides by enzymes in stomach and intestine to be absorbed. Better dispersion to small droplets will help digestion by increasing e of fat particles giving access for enzymes. In literature different combinations of fats, glycerides or fatty acids have been tested for in?uence on lymphatic absorption. No general agreements have been reached to which combinations are optimal but from literature it is clear that the fat composition play an important role as well as the amount of fat taken. Khoo et al (Pharm.Res., 20, 1460—1464, 2003) demonstrated that a formulated fat composition of only 600 mg was enough to trigger lipid metabolism in the GI tract and induce high tic absorption of the compound Halofantrine in fasted dogs. Further, the exogenous lipid supplied in the formulation was demonstrated to induce transport of nous lipid, as a -fold ?ow of lipid was found to be transported to the lymph, compared to the lipid from the formulation.
To be a successful drug ate in a formulation targeted for lymphatic absorption the compound has to have a log P of at least 5 and a high solubility in lipids. To ful?ll these requirements chemical modification of the compound may be ed by ment of a lipophilic moiety to the parent molecule, to increase the ilic properties of the compound to an extent that lymphatic transport is possible. The modi?ed compound is subsequent to absorption converted back to the original compound by enzymatic ge either in the blood stream or at the site of action. However, selection of a compound fulfilling these requirements will make it suited for lymphatic absorption but will not arily limit the variability in oral bioavailability unless the compound is taken together with a high fat meal.
Testosterone undecanoate is an example of such a compound used for treatment ofmale hypogonadism. When administered orally terone undergoes ive ?rst pass metabolism both during tion in the GI tract and in the liver. Testosterone is therefore not ble as a marketed oral product. A derivative of testosterone such as testosterone undecanoate has therefore been developed and ed for oral delivery. Testosterone undecanoate (TU) is a lipophillic ester pro—drug of testosterone having a log P of about 8.7. Testosterone undecanoate is formulated in Castor oil/Propylene glycol monolaurate (293 mg mixture) in a soft gelatin capsule as Andriol® capsules. The lymphatic absorption of TU from this formulations is however shown to be highly dependent upon intake of y fat. Therefore this formulation should always be taken with a normal meal to ensure absorption of testosterone undecanoate. As the absorption is extremely dependent on the food intake then absorption becomes very variable and often inadequate. According to the Andriol® label, the oral bioavailability of testosterone undecanoate in a patient in a fed state is more than 50 times that of a fasted state. Due to this food effect, oral testosterone noate is not a suitable therapy for patients who have a low food or low fat intake, such as many y ts. Thus, one of the main draw backs of this oral formulation is the variability in absorption and y unreliable oral bioavailability and ?uctuation in serum levels becoming below the therapeutic level which results in unreliable efficacy.
Abiraterone acetate is used for treatment of metastatic prostate cancer. The API has a low water solubility and a log P of 5. 1. The compound has a low permeability resulting in variable absorption. The API is marketed as an oral product Zytiga® to be taken on an empty stomach as the absorption of the API is highly le and sed upon food intake. Therefore intake of food increases the risk of severe side s of the drug.
Omega—3 oils such as triglycerides, ethyl esters, free fatty acids and derivatives thereof are used for pharmaceuticals and dietary supplements having a wide spectrum of biological bene?ts. The omega-3 oils are characterized by having a high Log P value 2 5 and a high solubility in lipids. However, when formulated in capsules such oils often shown an incomplete and variable absorption though a number of different absorption paths within the GI tract.
SUMMARY OF THE INVENTION The present inventors have realized that a certain fat composition comprising monoglycerides of long chain fatty acids and/or triglycerides of long chain fatty acids can support a compound having a log P of at least 5 so as to e lymphatic absorption of the compound in fed as well as in fasted state, and further achieve a high oral bioavailability and at the same time a low ility in absorption.
The present ion relates to a ition, such as a pharmaceutical composition comprising a lipophilic compound having a log P of at least 5 and carrying enough fat in a vehicle to control and achieve lymphatic absorption of the compound in fed as well as in fasted state.
Accordingly, the present invention relates to a pharmaceutical composition comprising nd having a log P of at least 5 and a vehicle, wherein the vehicle comprises (a) a fat ent in an amount suf?cient to achieve lymphatic absorption in a mammal, wherein the fat component is ed from a mono- glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids.
In a further aspect the present invention relates to a composition comprising a compound having a log P of at least 5 and a vehicle, wherein the vehicle comprises a fat component in an amount suf?cient to achieve lymphatic absorption in a mammal, wherein the fat component is selected from a mono-glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids.
In yet a further aspect the present invention s to a composition comprising a compound having a log P of at least 5 and a vehicle, wherein the vehicle ses (a) a fat component in an amount suf?cient to achieve lymphatic absorption in a mammal, wherein the fat ent is selected from a mono-glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids and (b) a tablets core composition suited for optimizing dosing and modifying release of the drug/vehicle system to target the lymph.
In yet another aspect of the present invention relates to a composition comprising a compound having a log P of at least 5, wherein the compound itself ses (a) a fat component in an amount ient to achieve lymphatic absorption in a , wherein the fat ent is selected from a mono— glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids and (b) a tablet core composition suited for optimizing dosing and modifying release of the compound/vehicle system to target the lymph.
In a further aspect the present invention relates to a composition comprising a lipophilic compound having a log P of at least 5, and a vehicle, wherein the vehicle comprises (a) a fat component in an amount of at least 500 mg suf?cient to achieve lymphatic absorption in a mammal, n the fat component is selected from a mono-glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids, wherein the long chain fatty acids in the monoglycerides are selected from fatty acid chains having from 14 to 24 carbon atoms and the long chain fatty acids in the triglycerides are selected from fatty acid chains having from 14 to 24 carbon atoms, and (b) a hydrophilic surfactant wherein the weight ratio (a):(b) is from about 10:1 to about 122. Such ition is typically selected from a liquid, a gel, a granule, a e or tablet.
In one embodiment the composition is a pharmaceutical composition.
In another ment the composition is a dietary composition.
In a r embodiment of the composition the fat component comprises a monoglyceride and a triglyceride of long chain fatty acids, wherein the weight ratio of triglycerides to monoglycerides is in a range from about 2.8:] to about 1:5.
In a still further embodiment of the composition the fat component is present in an amount suf?cient to enhance or promote intestinal lymphatic transport of the compound upon oral administration in the fasted state as well as in fed state, compared to a composition t the fat component.
In a further embodiment of the composition the amount of fat component is from 500 mg to 1200 mg.
In a further embodiment of the composition the amount of fat component is from 500 mg to 10 g.
Such as from 1500 mg to 10 g, 2000 mg to 8 g, 3000 mg to 7 g, 4000 mg to 6 g, or from 2000 mg to 6g.
In a still further embodiment the composition exhibits an AUC(O-inf) (fasted) / AUC(0-inf) (fed)) of at least about 0.4, such as at least about 0.8.
In a further embodiment of the composition the weight ratio of (a):(b) ranges from about 4:1 to about 1:2.
In a still further embodiment of the composition the long chain fatty acids in the monoglycerides are selected from linolenic acid, oleic acid, palmitic acid, linoleic acid, and c acid.
In a further embodiment of the composition the long chain fatty acids in the triglycerides are selected from linolenic acid, oleic acid, palmitic acid, linoleic acid, and stearic acid.
In a still further embodiment of the composition the fat component comprising a triglyceride of long chain fatty acids is selected from a naturally derived oil. In one embodiment the naturally derived oil is selected from soybean oil, olive oil, sesame oil, saf?ower oil, peanut oil, rapeseed oil, sun?ower oil, coconut oil, corn oil, sun?ower seed oil, cotton seed oil, palm oil, and arachis oil, as well as any combination thereof.
In a further embodiment of the composition the fat ent is selected from olive oil, soybean oil, es of olive oil and glycerol mono oleate, and mixtures of soybean oil and glycerol mono oleate. In one embodiment the fat component does not se any triglyceride but only monoglyceride, such as ol monooleate.
In a still further embodiment of the ition at least about 95% by weight of the lipophilic compound is present in the composition after 2 years of e at 25 °C and 60% relative humidity.
In a further embodiment of the composition the lipophilic compound is present in an amount from about 0.5% to about 60% by weight, and typically from about 01% to about 30% by weight based on 100% total weight of the composition.
In a still further embodiment of the composition the vehicle is self-emulsifying.
In a further embodiment the composition, upon dilution in d water, forms ts with a d50 of less than about 200 micrometer. In one embodiment the droplets have a d50 of less than about 150 micrometer, such as less than about 100 micrometer, such as less than about 40 micrometer, less than about micrometer, less than about 10 eter, or less than about 5 micrometer.
In a still further embodiment of the composition the lipophilic compound is in a solid core, such as a tablet core. In one embodiment the vehicle is adsorbed into the solid core. In a r embodiment the vehicle is adsorbed into the tablet core. In another embodiment the lipophilic nd is dissolved in the vehicle and adsorbed into the solid core. In a still further embodiment the lipophilic nd is dissolved in the vehicle and adsorbed into the tablet core.
In a further ment the composition is a tablet having a solid core comprising the lipophilic compound having a log P of at least 5, and the vehicle absorbed into the solid core, wherein the vehicle comprises (a) a fat component in an amount of at least 500 mg suf?cient to achieve lymphatic absorption in a mammal, wherein the fat component is selected from a lyceride of long chain fatty acids, a tri- glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids, wherein the long chain fatty acids in the monoglycerides are selected from fatty acid chains having from 14 to 24 carbon atoms and the long chain fatty acids in the triglycerides are selected from fatty acid chains having from 14 to 24 carbon atoms, and (b) a hydrophilic surfactant wherein the weight ratio (a):(b) is from about 10:1 to about 1:2; wherein the fat component is t in an amount suf?cient to enhance or promote intestinal lymphatic transport of the compound upon oral administration in the fasted state as well as in fed state, compared to a composition without the vehicle component in said solid core. In one embodiment the lipophilic compound is dissolved in the e and adsorbed into the solid core. In another embodiment the lipophilic compound is partly or fully formulated into the solid core and then the vehicle is ed into the solid core.
In a still further embodiment of the composition the solid core has a porosity of at least 30% volume, such as at least 40%, such as at least 50%, such as at least 55% such as at least 60%, for instance form 30% volume to 60% volume, or from 40% volume to 55% volume. Examples of such solid cores with high porosity are described in for instance European Patent ation EP1765297.
A particular useful composition is a solid core, wherein the solid core comprises a silicon dioxide in an amount of at least 40 % by weight of the total composition without the lipophilic compound.
When the composition is selected from a solid core, such core is typically a compressed or molded tablet core having a hardness of from 20N t0 150N.
In a further embodiment of the composition the hydrophilic surfactant is selected from a hydrophilic surfactant with a Hydrophile-Lipophile Balance (HLB) value of 10 or higher. Typically, the hydrophilic surfactant is selected from hydrogenated castor oil ethoxylates, polysorbates and any combination f.
In a still further embodiment of the composition the lipophilic compound is selected from erone acetate, acitretin, allylestrenol, alpha tocopherol, amidarone, aprepitant, atorvastatin, bexarotene, bromocriptine, candesartan, cinacalcet, clomiphene, diethyl stilbestrol, dihomo-gamma- linoleic acid, ne, ergocalciferol, feno?brate, fucidic acid, halofantrine, irbesartan, isotretinoin, itraconazole, lapatinib, liraglutide, loratidine, nandrolone ate, nel?navir, rtan, orlistat, posaconazole, ol, raloxifene, ritonavir, fen, telmisartan, teprenone, tipranavir, valsartan, and zuclopenthixol.
Each of these compounds constitute individual embodiments and may be elected as the speci?c lipophilic compound in any of the above embodiments and s of the present invention, such as for instance, erone acetate.
In a r embodiment of the composition the lipophilic compound is selected from a compound which has been d by ment of a lipophilic moiety to increase the lipophilicity of the lipophilic compound to at least log P of at least 5 making it suitable for lymphatic uptake. Typically, the compound is a pro-drug, such as an ester or amide. Examples of such pro-drugs are selected from paclitaxel docosahexaenoate, paclitaxel undecanoate, paclitaxel oleate and paclitaxel te, tide covalently attached to a fatty acid with at least 20 carbon atoms in an amide ion; leuprolide ntly attached to a fatty acid ester Via the aliphatic or aromatic hydroxyl group present in the peptide; propofol covalently attached to a fatty acid ester Via the phenolic aromatic hydroxy group; and testosterone undecanoate. Each of these modi?ed compounds constitute individual embodiments and may be elected as the speci?c lipophilic compound in any of the above embodiments and aspects of the present invention, such as for ce, paclitaxel docosahexaenoate.
In a special ment the present invention relates to a ition comprising abiraterone acetate, and a vehicle, wherein the vehicle comprises (a) a fat component in an amount of at least 500 mg suf?cient to achieve lymphatic absorption in a mammal, wherein the fat component is selected from a mono— glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids, wherein the long chain fatty acids in the monoglycerides are selected from fatty acid chains having from 14 to 24 carbon atoms and the long chain fatty acids in the triglycerides are ed from fatty acid chains having from 14 to 24 carbon atoms, and (b) a hydrophilic surfactant wherein the weight ratio (a):(b) is from about 10:1 to about 1:2, for use in the treatment of cancer, such as prostate cancer, e.g. castration-resistant prostate .
In another special embodiment the present invention relates to a composition comprising a paclitaxel prodrug, such as paclitaxel docosahexaenoate, paclitaxel undecanoate, paclitaxel oleate and paclitaxel stearate, and a vehicle, wherein the vehicle comprises (a) a fat component in an amount of at least 500 mg suf?cient to achieve lymphatic absorption in a mammal, wherein the fat component is selected from a mono- glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids, wherein the long chain fatty acids in the monoglycerides are selected from fatty acid chains having from 14 to 24 carbon atoms and the long chain fatty acids in the triglycerides are selected from fatty acid chains having from 14 to 24 carbon atoms, and (b) a hilic surfactant wherein the weight ratio (a):(b) is from about 10:1 to about 1:2, for use in the treatment of cancer, such as breast cancer, ovarian cancer, non-small cell lung cancer (NSCLC) and prostate cancer.
In a still further aspect the present invention s to a method for treatment of cancer in a mammal, such as a human, comprising stering a composition comprising a paclitaxel prodrug, such as axel docosahexaenoate, paclitaxel undecanoate, axel oleate and paclitaxel stearate, and a e, wherein the vehicle comprises (a) a fat component in an amount of at least 500 mg suf?cient to achieve lymphatic absorption in a mammal, wherein the fat component is selected from a mono-glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono— and tri—glyceride of long chain fatty acids, wherein the long chain fatty acids in the monoglycerides are selected from fatty acid chains having from 14 to 24 carbon atoms and the long chain fatty acids in the triglycerides are ed from fatty acid chains having from 14 to 24 carbon atoms, and (b) a hydrophilic surfactant n the weight ratio (a):(b) is from about 10:] to about 1:2, wherein the composition is effective to treat said cancer.
In a further aspect the present invention relates to a method for treatment of cancer in a mammal, such as a human, comprising administering a ition comprising abiraterone e, and a vehicle, wherein the vehicle comprises (a) a fat component in an amount of at least 500 mg suf?cient to achieve lymphatic tion in a mammal, wherein the fat component is selected from a mono-glyceride of long chain fatty acids, a yceride of long chain fatty acids, and a mono— and tri—glyceride of long chain fatty acids, wherein the long chain fatty acids in the monoglycerides are selected from fatty acid chains having from 14 to 24 carbon atoms and the long chain fatty acids in the triglycerides are selected from fatty acid chains having from 14 to 24 carbon atoms, and (b) a hydrophilic surfactant wherein the weight ratio (a):(b) is from about 10:] to about 1:2, wherein the composition is effective to treat said cancer.
In a still further aspect the present invention relates to a composition comprising an omega-3 oil and/or an omega-6 oil, and a vehicle, wherein the vehicle comprises (a) a fat component in an amount of at least 500 mg suf?cient to achieve lymphatic absorption in a , wherein the fat component is selected from a mono-glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono— and tri—glyceride of long chain fatty acids, wherein the long chain fatty acids in the monoglycerides are selected from fatty acid chains having from 14 to 24 carbon atoms and the long chain fatty acids in the triglycerides are selected from fatty acid chains having from 14 to 24 carbon atoms, and (b) a hilic tant wherein the weight ratio (a):(b) is from about 10:1 to about 1:2. In one embodiment the omega-3 oil and/or the omega-6 oil is selected from an omega-3 oil. In another embodiment the omega-3 oil and/or the 6 oil is ed from an omega-6 oil. In yet another ment the omega-3 oil and/or the omega-6 oil is selected from a mixture of an omega-3 oil and an omega—6 oil. r embodiments may be elected from any of the above described embodiments in connection with the above aspects of a composition comprising a lipophilic compound having a log P of at least 5 and embodiments thereof as understood by the skilled person.
In a further aspect the present invention relates to a tablet comprising (i) a solid core and (ii) a composition comprising an omega—3 oil and a vehicle, wherein the vehicle comprises (a) a fat component in an amount of at least 500 mg suf?cient to achieve lymphatic absorption in a mammal, wherein the fat component is selected from a mono-glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids, wherein the long chain fatty acids in the monoglycerides are selected from fatty acid chains having from 14 to 24 carbon atoms and the long chain fatty acids in the cerides are selected from fatty acid chains having from 14 to 24 carbon atoms, and (b) a hydrophilic surfactant wherein the weight ratio ) is from about 10:1 to about 1:2; n the solid core comprises a silicon dioxide and n the composition comprising the omega-3 oil and the vehicle is adsorbed into the solid core. Further ments may be elected from any of the above described embodiments in connection with the above aspects of a composition comprising a lipophilic compound having a log P of at least 5 and embodiments thereof as tood by the skilled person.
In a further aspect the present invention relates to a tablet comprising (i) a solid core and (ii) a ition comprising an omega-3 oil and a vehicle comprising a hydrophilic surfactant; wherein the solid core comprises a silicon dioxide and wherein the composition comprising the omega-3 oil and the vehicle is adsorbed into the solid core. Further ments may be elected from any of the above described embodiments in connection with the above s of a composition comprising a lipophilic compound having a log P of at least 5 and embodiments thereof as understood by the skilled person. In r embodiment the weight ratio of 3 oil:surfactant ranges from about 3:2 to about 10:1.
In a still further aspect the present invention relates to a tablet comprising a solid core and an omega- 3 oil, wherein the solid core comprises silicon dioxide and wherein the omega—3 oil is adsorbed into the solid core. In one embodiment the solid core has a porosity of at least 30% volume, such as at least 40%, such as at least 50%, such as at least 55%, such as at least 60%, for instance form 30% volume to 60% volume, or ?om 40% volume to 55% volume. In a particular useful tablet the silicon dioxide is present in an amount of at least 40 % by weight of the total composition without the omega-3 oil.
In a further embodiment of the tablet comprising a solid core, the solid core enhance or promote intestinal lymphatic transport of the omega oil upon oral administration in the fasted state as well as in fed state, compared to a composition or omega—3 oil not adsorbed into said solid core. In one embodiment the omega-3 oil is present in an amount from about 0.5% to about 80% and typically from about 30 to about 60% by weight based on 100% total weight of the solid core.
In a further aspect the present invention relates to a tablet sing a solid core, wherein the solid core comprises a silicon dioxide and an appropriate excipient to improve the poor compressibility of silicon dioxide to be able to produce high—level silicon e tablets t cracking and g. Preferably, the appropriate excipient is ed from Hypromellose 100 cps, maltodextrin, and low—substituted Hydroxypropyl cellulose. In one embodiment the tablet is empty of any liquid composition and any pharmaceutical nd, or omega-3 oil. In r embodiment the solid core has a porosity of at least % volume, such as at least 40%, such as at least 50%, such as at least 55%, such as at least 60%, for instance form 30% volume to 60% volume, or from 40% volume to 55% volume. In a further embodiment the solid core further comprises an antioxidant, such as t limitation alpha-Tocopeherol, gamma- Tocopherol, ascorbyl palmitate, ascorbic acid, Butylated Hydroxytoluene, Butylated Hydroxyanisole, citric acid or propyl gallate.
Further objects and advantages of the present invention will appear from the following description, and claims.
DESCRIPTION OF THE INVENTION It is speculated r effective lymphatic absorption of lipophilic compounds with high log P and high solubility in triglycerides can be achieved with low amounts of lipid relevant for single dose formulations.
Improving the lymphatic tion of lipophilic compounds can be accomplished in two ways.
Solubilization of fat components into micelles can be ed by proper selection of surfactants.
Solubilization will improve both the rate of digestion of fat and the amount of fat and the lipophilic compound transported over the unstirred water layer. Solubilization of lipophilic nd and formulation is part of the technology concept of the present invention.
Further, the proper selection of fat components which trigger lipid metabolism in the GI tract and induce release ofthe lipophilic compound into the lymphatic system is part of the technology concept of the present invention. The contrast between the reported data from Khoo et al (Pharm.Res., 20, 1460-1464, 2003) and Schnabel et a1 (Clin Endocrin. 66, 579-585, 2007) have made the present inventors realize that both fat composition and amount of fat are important ters if the system shall control the lymphatic uptake. The amount of fat is an issue ally if the lipophilic compound is taken in fasted state, and if the fat composition is not optimal or the amount is too low, variation in absorption will be the expected result.
It is most likely that an ef?cient formulation based on incorporation of larger amount of selected solubilizers and fats will result in an increase in bioavailability and/or decrease in variability compared to current formulations of a lipophilic compound. r, having the formulation to l the lymphatic uptake will e the requirement for simultaneous food intake.
The present invention relates to a composition sing a compound having a log P of at least 5 and a vehicle, wherein the vehicle comprises (a) a fat component in an amount suf?cient to control and achieve lymphatic tion in a mammal, wherein the fat component is selected from a mono-glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids.
Examples of compounds with a log P of at least 5 that may be suitable for formulation according to the present invention e but is not d to the following: Abiraterone acetate, acitretin, allylestrenol, alpha tocopherol, amidarone, aprepitant, atorvastatin, bexarotene, bromocriptine, candesartan, cinacalcet, clomiphene, diethyl stilbestrol, -gamma- linoleic acid, ebastine, ergocalciferol, feno?brate, fucidic acid, halofantrine, irbesartan, isotretinoin, itraconazole, lapatinib, liraglutide, loratidine, nandrolone decanoate, nel?navir, olmesartan, orlistat, posaconazole, ol, raloxifene, ritonavir, imus, tamoxifen, telmisartan, teprenone, tipranavir, valsartan, zuclopenthixol.
The lipophilic compound may be in free acid, free base or salt form, and mixtures of lipophilic nds may be used where therapeutically effective.
In another embodiment the invention relates to a composition comprising a compound which has to be modi?ed e.g. by attachment of a lipophilic moiety to increase the ilicity ofthe compound to at least log P of at least 5 making it suitable for lymphatic uptake. Such lipophilic moiety can be in the form of an ester or an amide. Subsequent absorption the binding of the moiety is cleaved by endogenous peptidases or hydrolysed by ylases thereby liberating the active molecule in the blood stream or at the site of eutic action. The composition r comprises a vehicle, wherein the vehicle comprises (a) a fat component in an amount suf?cient to control and achieve lymphatic absorption in a mammal, wherein the fat component is selected from a mono-glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids.
Paclitaxel is an example of a compound having a log P less than 5 that can be esteri?ed to gain a lipophilicity high enough for lymphatic absorption in said composition. Examples of such esters are without limitation docosahexaenoate, undecanoate, oleate and stearate.
Propofol is another example of a compound that can be esteri?ed to a fatty acid ester, such as without limitation propofol-acetate, ol-undecanoate, propofol palmitate, propofol oleate, propofol- hexexoate and propofol-eicosapentanoate.
Testosterone is an example of another compound having a log P less than 5 that can be esteri?ed to gain a lipophilicity high enough for lymphatic absorption in said ition. Examples of such esters without tion are undecanoate, palmitate and .
Yet another group of compounds which has to be modi?ed is the peptides that can be lipophilic modi?ed with an ester or an amide. The size and length of the lipophilic moiety attached to the peptide can be varied to gain ent lipophilicity of said compound. Octreotide is an example of a relative hydrophilic small peptide having a log P around 1. By attachment of a fatty acid with at least 20 carbon atoms in an amide formation, a compound with a log P of at least 5 is obtained. Another example is the nonapeptide leuprolide having a log P of about 3 where a fatty acid ester can be formed on the aliphatic or aromatic hydroxyl group t in the peptide providing a log P of at least 5.
In yet another embodiment of the invention the ition comprises a compound being an omega— 3 or an omega-6 oil or a mixture thereof such as triglycerides, free 3—fatty acids, omegafatty acids ethyl esters, salts or derivatives thereof having a log P of at least 5. The composition further comprise a vehicle, wherein the vehicle comprises (a) a fat ent in an amount suf?cient to control and achieve lymphatic absorption in a mammal, wherein the fat component is selected from a mono-glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids.
Examples of omegafatty acids are but not d to alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA and an e of an omega-6 fatty acid is gamma— linolenic acid (GLA). es of omega-3 fatty acid ethyl esters are but not limited to EPA ethyl ester: (all-Z)- 5,8,11,14,17-Eicosapentaenoic acid ethyl ester and DHA ethyl ester: (all-Z)—4,7,10,13,16,19— Docosahexaenoic acid ethyl ester. Each of these omega-3 oils constitute individual embodiments and may be elected as the speci?c lipophilic compound or omega-3 oil in any of the above embodiments and aspects of the present invention, such as for instance, ALA. Each of these omega-6 oils constitute individual embodiments and may be elected as the speci?c ilic compound or omega-6 oil in any of the above embodiments and aspects of the present invention, such as for instance, GLA.
In an embodiment the e r comprises (b) a hydrophilic surfactant, wherein the weight ratio (a):(b) is from about 10:1 to about 1:2, such as from about 4:1 to about 1:2. The weight ratio (a):(b) may range from about 40:60 to about 80:20, such as from about 50:50 to about 70:30. In one embodiment, the ratio (a):(b) ranges from about 55:45 to about 65:35, such as about 60:40.
The hydrophilic surfactant may be any described herein. Suitable hilic surfactants include hydrogenated castor oil ethoxylates (such as Polyoxyl 35 castor oil), polysorbates (such as polysorbate 80) or any other hydrophilic surfactant with a Hydrophile-Lipophile e (HLB) value of 10 or higher, and any combination of any of the foregoing.
In another embodiment the fat component further comprises a triglyceride of long chain fatty acids, n the weight ratio of triglycerides to monoglycerides is in a range from about 2.8:] to about 1:5. When one or more cerides are present in the fat component, the ratio of triglyceride to monoglyceride may, for instance, range from about 2:1 to about 1:5, such as from about 3:2 to about 1:4. In one embodiment, the ratio is from about 1:1 to about 1:3.
In a further embodiment the fat component is present in an amount suf?cient to enhance or promote intestinal lymphatic ort of the lipophilic compound upon oral administration in the fasted state as well as in fed state, compared to a composition without the fat component.
In a further embodiment the amount of fat component is at least about 500 mg, such as at least 600 mg, at least 700 mg, at least 800 mg, at least 1000 mg, such as from about 500 mg to about 1000 mg.
In a further embodiment of the composition the amount of fat component is from 500 mg to 10 g.
Such as ?om 1500 mg to 10 g, 2000 mg to 8 g, 3000 mg to 7 g, 4000 mg to 6 g, or from 2000 mg to 6g.
It is known to the person skilled in the art that high amounts of fat may have to be administered in more than one composition, which makes it clear that for instance 2400 mg fat may preferably be administered as 6 s of 400 mg fat each, or as 3 dosages of 800 mg each. ore a ition of the present invention is intended to mean one or more compositions sing, typically, at least 500 mg fat in total, for instance 5 capsules ning 100 mg fat each or e.g. 6 capsules comprising 400 mg fat each.
In a still further embodiment the composition ts an AUC(0_in0(fasted)/ AUCQM (fed)) of at least about 0.4. The present composition exhibits enhanced bioavailability and a reduced food effect. Without being bound by or limited to theory, it is believed that the formulation es this result by controlling and enhancing absorption of the lipophilic compound by the intestinal lymphatic system rather than by way of portal circulation. In a preferred embodiment, the formulation exhibits an AUC0_inf(faSted) / AUCO.inf(fed) (i.e., AUC(0_1-n0 (fasted)/ AUC(0_in0 (fed)) of at least about 0.4. In r preferred embodiments, the formulation exhibits an AUCO- inf (fasted) / AUCO-inf (fed) of at least about 0.6, at least about 0.7, or at least about 0.8.
The long chain fatty acids in the monoglycerides and triglycerides may have range in length from 14 to 24 carbon atoms.
In a further embodiment the long chain fatty acids in the monoglycerides are selected from fatty acid chains having from 14 to 24 carbon atoms, such as from 16 to 20 carbon atoms.
In a still ?lrther embodiment the long chain fatty acids in the triglycerides are selected from fatty acid chains having from 14 to 24 carbon atoms, such as from 16 to 20 carbon atoms.
Suitable fatty acids for the monoglycerides and triglycerides include, but are not limited to, (A) linoleic acid (18:2), (B) oleic acid (18:1), (C) palmitic acid (16), (D) linoleic acid (18:3), and (E) stearic (18:0). (The ?rst number in the parentheticals in the prior ce refers to the number of carbon atoms in the fatty acid chain, and the second number refers to the degree of unsaturation (e.g., 1 refers to 1 double bond).).
When triglycerides are present in the fat component they may typically be present as oils. In a further embodiment the fat ent comprising a triglyceride of long chain fatty acids is selected from an oil such as soybean oil, olive oil, sesame oil, saf?ower oil, or any combination f.
Sometimes the fat component does not comprise any triglyceride but only monoglyceride such as glycerol monooleate.
In another embodiment, the fat component comprises ycerides and triglycerides.
In a further embodiment, the fat component is selected from olive oil.
In a still further embodiment, the fat component is selected from soybean oil.
In a still further embodiment, the fat component is selected from omega 3 oil.
In a further ment, the fat ent is selected from a mixture of olive oil and glycerol mono oleate.
In a still further embodiment, the fat ent is selected from a mixture of soybean oil and glycerol mono oleate.
In a still further embodiment, the fat component is selected from omega 3 oil and glycerol mono .
The vehicle ation may be a liquid and it may also be self-emulsifying when introduced to aqueous media. In a certain embodiment, the composition, upon dilution in puri?ed water, forms droplets with a d50 of less than about 50 um. In a further embodiment the composition, upon dilution in puri?ed water, forms droplets with a dso of less than about 200 micrometres, such as less than about 150 micrometres, such as less than about 100 micrometres, such as less than about 40 micrometres, such as less than about 20 micrometres, less than about 10 etres, or less than about about 5 micrometres, such as droplets having a dso ranging from about 0.01 to about 200 um, such as from about 0.1 to about 40 pm.
In a further embodiment the lipophilic compound is in a solid core, such as a tablet core.
In a still further embodiment the vehicle is adsorbed into the solid core. When the composition is in the form of a , the lipophilic compound can optionally be dissolved in the vehicle or the lipophilic compound can optionally be fully or partly included in the tablet core before adsorbing of the vehicle. In an embodiment the lipophilic compound is dissolved in the vehicle and adsorbed into the solid core.
When the dosage form is solid it may be a ssed or molded tablet having a hardness of from about 20 N to about 150 N.
In a further embodiment the lipophilic compound (having a log p of at least 5) is a pro-drug, such as an ester or an amide.
The ition of the present ion may be selected from a liquid, a gel, a granule, a capsule or a tablet. In one embodiment, the composition, e.g. oral, could be a liquid. In such case the lipophilic compound is solubilized in the vehicle. In another ment, the composition, e.g. oral, is a e, and in this case the lipophilic compound is solubilized in the vehicle and is ?lled into soft or hard capsules.
In a further aspect the present invention relates to an oral dosage form, such as a solid oral dosage form, comprising the pharmaceutical composition of the invention. The composition may be orated into a solid oral dosage form having a t as discussed below. The compound can be solubilized in the vehicle or it can be fully or partly added to the composition before ssion it into a tablet.
Furthermore, the absorption to a solid core, such as a tablet core, can be bene?cial in delaying the release of the SEED system within the gastrointestinal tract. When the self-emulsifying drug delivery system is formulated in a capsule the self-emulsifying drug delivery system is typically released immediately after oral intake, whereas when the self-emulsifying drug delivery system is absorbed in a tablet core, the dissolution of the self-emulsifying drug delivery system is modi?ed and delayed somewhat. This effect can be observed when comparing the dissolution pro?les of a self-emulsifying drug ry system from either a e or the tablet. Surprisingly, the tablet reduces the release rate of the self-emulsifying drug ry system also help in decreasing the variability in absorption, thus help the absorption pro?le further to be nearly independent of food intake. This is an especially important and useful property for compounds having a narrow therapeutic window.
The bene?t of having the tablet core as the dosage form, has also been shown even without the active compound initially being dissolved in a self-emulsifying drug delivery system. This is ally useful when the compound is a liquid and a high load of the compound is needed in the dosage form and especially such as for omega 3 fatty acids, triglycerides, ethyl esters and derivatives thereof where higher tion and lower variability and elimination of ?sh taste or burbs can be achieved by dosing the oil when ed in the tablet compared to when it is dosed as a conventional capsule.
Yet another embodiment is an oral tablet comprising (i) an adsorbent excipient, (ii) ally a binder or release enhancing agent, (iii) optionally a disintegrant or other standard tablet excipients, (iv) a composition of the present ion.
The solid oral dosage form may be prepared by preparing a granulate of the adsorbant excipient and optionally (a) binder(s) and preparing a tablet comprising an adsorbent excipient, optionally a binder, optionally a release enhancing agent, optionally a disintegrant and optionally other normal tablet excipients (binders, lubricants, ?ow enhancers etc), and adsorbing the mixture of a nd in the vehicle into the tablets, until the lipophilic compound is adsorbed, for example, to about 50% or more (e.g., 70% or more) of the adsorbing capacity.
The adsorbtion may be performed by placing the tablet in an excess amount of the lipophilic compound in the vehicle for a suf?cient amount of time. In an embodiment, the adsorbing is performed under pressure. The time period of adsorbing the compound may be from about 15 minutes to about 10 hours.
Yet another ment is a method of delivering a compound to the systemic circulation through the lymphatic transport system by the oral administration to a mammal subject of a solid oral dosage form or oral pharmaceutical formulation of the present invention. ably, the solid oral dosage form includes at least about 300 mg (e. g., at least about 400 mg, at least about 500 mg, at least about 550 mg, or at least about 600 mg) of the long chain lipids that is a mono- glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, or a mono- and tri-glyceride of long chain fatty acids.
In a further embodiment, the total content of long chain lipids in the solid oral dosage form ranges from about 600 to about 800 mg, such as from about 600 to about 700 mg.
A typical embodiment of the solid oral dosage form comprises (A) a solid carrier comprising adsorbent Silicon dioxide; and (B) a mixture comprising the lipophilic compound in a vehicle comprising (a) a fat component in an amount suf?cient to achieve lymphatic absorption in a mammal, wherein the fat component comprises a monoglyceride of long chain fatty acids, and (ii) optionally, one or more hydrophilic surfactants, n (ai) the mixture is adsorbed in the porous silicon e, and (bi) the solid oral dosage form comprises from about 600 to about 1000 mg of long chain lipids (e.g., from about 600 to about 800 mg).
As explained herein the pharmaceutical composition of the present invention may be administered so as to avoid the ement of orally stering a compound in the fed state.
In a further aspect the present invention s to a method of preparing the composition of the invention comprising formulating the lipophilic compound with a vehicle wherein the vehicle comprises (a) a fat component in an amount of at least 500 mg suf?cient to achieve lymphatic absorption in a mammal, wherein the fat ent is selected from a mono-glyceride of long chain fatty acids, a yceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids, wherein the long chain fatty acids in the monoglycerides are selected from fatty acid chains having from 14 to 24 carbon atoms and the long chain fatty acids in the triglycerides are ed from fatty acid chains having from 14 to 24 carbon atoms, and (b) a hydrophilic surfactant wherein the weight ratio (a):(b) is from about 10:] to about 1:2, such that oral administration of the composition in the fed or fasted state facilitates delivery of the compound to the systemic circulation through the lymphatic transport system.
The solid oral dosage form of the present invention can provide a number of advantages over conventional methods for the delivery of a compound within the subject. For example, the solid oral dosage forms comprising the composition of the present ion can provide suf?cient oral ilability of the lipophilic compound and at the same time a low variability in absorption regardless of whether the subject is in the fed or fasted state. Accordingly, in the s of ent described, the solid oral dosage forms may be administered in both the fed or fasted state.
This is a particular advantage when administering narrow therapeutic indexed drugs (lipophilic compounds) where variability in absorption due to food could provide either a risk of severe side-effects or insuf?cient drug levels. This is also an advantage when treating an elderly population, who typically does not eat a suf?cient amount of fat to achieve satisfactory absorption of a drug which is dependent upon food intake to be absorbed.
The solid oral dosage forms of the present invention may substantially avoid passage of the compound to the liver via the portal blood.
This is an advantages for compound undergoing extensive metabolism when passing the GI tract barrier or being ates for the P-GP ef?ux pump and therefore not being absorbed through the portal vein in suf?cient amount to achieve therapeutic drug levels or for drugs having a high ?rst pass metabolism making suf?cient absorption impossible.
The formulation in the form of a tablet may have several advantages, including reduced food , the possibility of including functional coatings, oxygen tion, targeted release, use of excipients which are not compatible with capsules, r production process, and use of standard equipment.
Compound The lipophilic compound may be either a pro-drug or a salt of the drug as explained above. The nd should have a log P of at least 5.
As explained above the compound may be solubilized in the vehicle before adsorbing into the solid adsorbent of the solid oral dosage form or the compound may be solubilized in the vehicle before ?lling into a capsule.
In a typical embodiment the oral dosage form includes the compound as partly or fully incorporated into a tablet core together with an adsorbent and the vehicle is ed into this tablet core to create the solid oral dosage form. The vehicle adsorbed can either be without or having some of the compound lized.
In yet r embodiment the compound itself is without being solubilized in the vehicle adsorbed into the solid oral dosage form. This is ally useful when the API (lipophilic compound) is a liquid and a high drug load is needed in the dosage form and especially for compounds such as for omega 3 fatty acids, triglycerides, ethyl esters and derivatives thereof where higher absorption and lower variability and elimination of ?sh taste and burbs can be ed by dosing the oil absorbed in a tablet compared to when it is dosed as a tional e.
The Vehicle The vehicle may be composed from lipids (mono- and/or triglycerides) and optionally hydrophilic surfactants as explained herein.
By lipids is understood to refer to, if not indicated otherwise, saturated, mono-unsaturated and saturated fatty acids and derivatives thereof. Derivatives e esters such as mono-, di- and triglycerides, as well as phospholipids or other glyceride esters.
The lipids may be composed of long chain fatty acids of from C14 to C24 or a derivative thereof, indicating from 14 carbon atoms in the fatty acid chain up to 24 carbon atoms in the fatty acid chain. The fatty acid may be a saturated, monounsaturated or polyunsaturated fatty acid or a derivative thereof. Each chain in the fatty acid or glyceride may have, for example, 0, l, 2, or 3 double bonds. The term "long chain lipid" refers to long chain (i.e., C14 or r, such as C14-C24 or C16-C1g) fatty acids, as well as derivatives of long chain fatty acids. Examples of suitable lipids for the vehicle include those which stimulate the production of nous lipid such as those described in US. Patent No. 338, the entire contents of which is incorporated herein by reference.
The lipids may be formulated with the lipophilic compound in the form of a naturally derived oil, such as soybean oil, olive oil, peanut oil, rapeseed oil, sun?ower oil, coconut oil, corn oil, er seed oil, cotton seed oil, palm oil, arachis oil, saf?ower oil, omega 3 oils or a combination thereof. Other suitable lipids include, but are not limited to, mono and di glycerides of the entioned oils, glycerol mono- oleate, glyceryl monolinoleate, and any combination of any of the foregoing.
The lipid(s) may be used alone or in combination with one or more. In one embodiment, the lipids alone or in ation with a surfactant stimulate the production of endogenous lipid or otherwise enhance or promote lymphatic transport of the drug or drug derivative. For instance, the vehicle may be selected from long chain lipids, and long chain lipids in combination with a hydrophilic surfactant.
Examples of surfactants which may be le include esters of mono or di—glycerides, (such as the acetic, succinic, , citric or tartaric esters), propylene glycol, mono or di—esters of fatty acids, polyglycerol esters of fatty acids, acid and ester ethoxylates of fatty acids, sorbitan esters of fatty acids, transesteri?cation products of natural or hydrogenated vegetable oil triglycerides and polyalkylene polyol, l ethoxylates, polyoxyethylene or polyoxypropylene copolymers, phospholipids, polyoxyethylene sorbitan fatty acid derivatives (such as polysorbates, e. g., polysorbate 80), castor oil or hydrogenated castor oil ethoxylates, for e Polyoxyl 35 castor oil/Cremophor ELTM, anionic surfactants, such as sodium lauryl sulphate or sodium oleate, alkylphenol surfactants, as well as mixtures of such surfactants. In such combinations, the surfactant may act to assist uptake of the fatty acid from the inal lumen. In one embodiment, a hydrophilic surfactant with an HLB value >10, such as Cremophor ELTM, is used, optionally in combination with a co—surfactant, which may be a hydrophobic surfactant with a HLB value < 10.
Typically, the vehicle comprises a lipid selected from olive oil, soybean oil, omega 3 oils, glycerol monooleate, and any combination of any of the foregoing. In one embodiment, the vehicle comprises olive oil and glycerol monooleate. In r embodiment, the vehicle comprises n oil and glycerol monooleate. In yet another embodiment, the vehicle comprises omega 3 oil and glycerol monooleate.
When, the vehicle ses a surfactant it is typically selected from polysorbate 80, polyoxyl 35 castor oil, and any combination of any of the foregoing.
In an embodiment, the vehicle comprises (a) the lipids olive oil and glycerol eate and (b) the surfactant polyoxyl 35 castor oil.
In a preferred embodiment, the vehicle comprises (a) the lipids soybean oil and glycerol monooleate, and (b) the surfactant polyoxyl 35 castor oil.
In another preferred embodiment, the vehicle ses (a) the lipids olive oil and glycerol monooleate, and (b) the surfactants polysorbate 80 and polyoxyl 35 castor oil.
In a further ment, the vehicle comprises a mixture of (a) long chain lipids, and (b) surfactants (hydrophilic surfactants). The weight ratio of (a):(b) may range from about 8:1 to about 1:6. For instance, the weight ratio of (a):(b) may be from about 4:1 to about 1:2. In one embodiment, the weight ratio of (a):(b) ranges from about 3:1 to about 1:2. In r ment, the weight ratio of ) ranges from about 2:1 to about 1:1. In one preferred embodiment, the weight ratio of (a):(b) is about 3:2.
The vehicle is preferably present in an amount suf?cient to enhance or promote lymphatic transport of the lipophilic compound. See Porter et al., Pharm. Res. 20(9): 1460-1465 (2003). In one embodiment, the fat ent is present in an amount of at least about 500 mg. For e, the amount can be from about 0.05 to about 4 g, such as from about 0.1 to about 1 g, corresponding to an amount which could be readily incorporated into a single solid oral dosage form. In another embodiment, the fat component is present in an amount that is at least about 600 mg, for example, from about 600 mg to about 1200 mg or from about 600 mg to about 1000 mg. In a further embodiment of the fat component is present in an amount that is at least 500 mg to 10 g. Such as from 1500 mg to 10 g, 2000 mg to 8 g, 3000 mg to 7 g, 4000 mg to 6 g, or from 2000 mg to 6g.
The vehicle may be formulated as lipid based emulsions or micro emulsions, or self-emulsifying or self-micro emulsifying formulations. Self-emulsifying and self-micro emulsifying formulations are those which spontaneously form emulsions or micro emulsions on contact of the contents of the solid oral dosage form with the gastric or intestinal ?uids and which are commonly termed self-emulsifying drug delivery systems (SEDDS) or self—micro fying drug delivery systems (SMEDDS). The lipophilic compound is intended to be solubilized in the vehicle either before or after adsorbing of the vehicle into the oral dosage form.
The Solid Carrier The solid carrier, that is the granulate, can be compressed in the form of a tablet that comprises an adsorbent excipient, that is silicon dioxide, and optionally binder(s) and/or a egrant. The solid tablet may be inert or atively the solid tablet may have incorporated the lipophilic compound in part or fully.
The solid carrier can be in the form of a . The solid r is capable of adsorbing a e.
When the solid r is in the form of granules, the median particle size of the granules may range from about 5 s to about 600 microns, for example from about 10 to about 300 microns. Granules may be compressed to form a tablet which is used as the solid carrier.
The Adsorbent Excipient The adsorbent excipient typically forms the bulk of the solid carrier. The adsorbent excipient (and the solid carrier) has a porosity of, for example, greater than about 10% v/v, such as greater than about 15% v/v, r than about 20% v/v, greater than about 30% V/v or greater than about 30% v/v. In a preferred embodiment, the porosity is greater than about 30% v/v, for example, from about 30 to about 50% v/v. In another embodiment, the ty is up to about 97% (e. g., from about 90 to about 94%) (such as Zeofree 5170 or Aeroperl 300).
The ent excipient may have a median le size of from about 5 microns to about 600 microns, for example from about 10 to about 300 microns. In one embodiment, the porous excipient may have a particle size of from about 10 microns to about 150 microns.
The solid carrier may include the adsorbent excipient at a concentration of about 20% w/w or more, such as about 25% w/w or more, about 30% w/w or more, about 35% w/w or more, about 40% w/w or more, about 45% w/w or more, about 50 w/w or more, about 60% w/w or more, about 70% or more, about 80% or more, about 90% or more, about 95% or more, or about 98% or more. In additional embodiments, the adsorbent excipient is present at a concentration of from about 20% to about 95% w/w, such as from about % to about 90% w/w, from about 50% to about 90% w/w, from about 60% to about 90% w/w from about 70% to about 90% w/w from about 65% to about 85% w/w from about 75% to about 85% w/w or from , , about 70% to about 80% w/w, based on 100% total weight of the solid carrier.
Many adsorbent excipients are found in the group of metal oxides and metal silicates. It was found that silicon dioxide was more inert to the added active ingredients compared to other adsorbent excipients.
Silicon dioxide however does not compress well and even for the skilled person it is not easy to e tablets with high levels of silicon dioxide. High levels of adsorbent excipient will be needed to adsorb the amount of liquid needed for this ion. Part of the invention is therefore the ion of appropriate excipients to improve on the poor compressibility of silicon dioxide to be able to produce high- level silicon dioxide tablets t cracking and capping. To achieve this, a very long list of binder excipients have been tested at relevant levels. Most of these formulations produced tablets with capping and poor ve properties with the result oftablets falling apart. The examples of solid carries given in this paper demonstrate the preferred binding excipients for the use with silicon dioxide.
In a red embodiment, the ent excipient is a silicon dioxide, such as Zeofree 5170 able from J.M. Huber Corporation) or Aeroperl (available from Evonik industries). onal Excipients The solid core of the oral dosage form, such as , may further comprise one or more pharmaceutically acceptable excipients. Examples of such excipients include, but are not limited to, ?llers, diluents, binders, lubricants, glidants, enhancers, wetting agents, surfactants, antioxidants, metal gers, pH-adjusting agents, acidifying agents, alkalizing agents, preservatives, buffering agents, chelating agents, stabilizing agents, ng agents, complexing agents, emulsifying and/or solubilizing agents, absorption enhancing agents, modify release agents, ?avoring agents, taste-masking agents, humectants, and sweetening agents.
Examples of suitable ?llers, diluents and/or binders include lactose (e.g. spray-dried lactose, (X.- lactose, B-lactose), rystalline cellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose (HPMC), methylcellulose, hydroxyethylcellulose, sodium carboxymethylcellulose, carboxymethylene, carboxymethylhydroxyethylcellulose and other cellulose derivatives, sucrose, agarose, sorbitol, mannitol, dextrins, maltodextrins, starches or modified starches ding potato starch, maize starch and rice starch), m phosphate (e.g. basic calcium phosphate, calcium hydrogen ate, dicalcium phosphate hydrate), calcium sulfate, calcium carbonate and potassium hydrogen ate.
Examples of metal scavengers include, but are not limited to, tartaric acid, citric acid, oxalic acid, EDTA and salts thereof, and DPTA ylenetriaminepentaacetic acid) and salts thereof.
Examples of antioxidants e, but are not limited to, BHT, BHA, propyl gallate, tocopherols, TBHQ (t—butyl hydroquinone), and ascorbyl palmitate.
Examples of diluents include, but are not limited to, calcium carbonate, c calcium phosphate, tribasic calcium phosphate, calcium sulfate, microcrystalline cellulose, powdered ose, dextrans, dextrin, dextrose, fructose, kaolin, lactose, mannitol, sorbitol, starch, pregelatinized starch, sucrose, and sugar.
Examples of binders include, but are not limited to, acacia, alginic acid, agar, calcium carrageenan, sodium carboxymethylcellulose, microcrystalline cellulose, dextrin, ethylcellulose, gelatin, liquid glucose, guar gum, hydroxypropyl methylcellulose, cellulose, pectin, PEG, povidone, maltodextrin and pregelatinized starch.
Examples of glidants and lubricants include, but are not limited to, stearic acid, ium stearate, calcium te or other metallic stearate, talc, waxes and glycerides, light mineral oil, PEG, glyceryl behenate, colloidal silica, hydrogenated vegetable oils, corn , sodium stearyl fumarate, polyethylene glycols, alkyl sulfates, sodium benzoate, and sodium acetate.
Examples of antioxidants include, but are not limited to, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, potassium sul?te, propyl gallate, sodium formaldehylde sulfoxylate, sodium metabisul?te, sodium thiosulfate, sulfur dioxide, erol, tocopherol e, tocopherol hemisuccinate, and TPGS or other tocopherol derivatives. The concentration of an antioxidant and/or a stabilizing agent in the tablet may be, for example, from about 0.1% w/w to about 5% w/w (based upon 100% total weight of the tablet t any ed compound and lipids/vehicles).
Examples of disintegrants include, but are not limited to, croscarmellose sodium, crospovidone, low- substituted Hydroxypropyl ose (L-HPC), polacrilin potassium, carboxymethylcellulose sodium, carboxymethylcellulose calcium, sodium alginate, sodium starch glycolate, starch or starch pregelatinized.
Solid Oral Dosage Form The amount of solid carrier in the solid oral dosage form may vary depending on its ty, as the liquid formulation. The solid dosage form preferably includes at least 600 mg of fats (lipids) and ent surfactants to allow for lymphatic absorption in the fasted state.
Since the solid oral dosage form, such as tablet or e, is intended for oral ingestion by a mammal, such as a human subject, the solid oral dosage form preferably weighs from about 50 mg to about 5000 mg, such as from about 200 mg to about 2000 mg, or from about 600 mg to about 1500 mg. In one embodiment, the solid oral dosage form weighs from about 700 mg to about 1200 mg.
The solid oral dosage form (e.g., oral tablet) described herein may optionally contain one or more coatings, such as a sub-coating and/or modi?ed release coating (e.g. an enteric coating). The sub-coating may be, e.g., Opadray AMB OY-B. The c coating may contain, e.g., Acryl EZE, dimethicone and triethyl citrate.
In one embodiment, the solid oral dosage form does not have a coating. In a preferred embodiment, the solid oral dosage form does not have an enteric coating. In another embodiment, the solid oral dosage form does not have a modi?ed release coating. In a preferred embodiment, the solid oral dosage form provides immediate release of the drug or drug derivative. In yet r embodiment, the solid oral dosage form provides extended release of the drug or drug derivative.
The solid oral dosage form may be in the form of a tablet. In one embodiment, the tablet is a compressed or molded tablet, e.g., having a hardness of from about 20 N to about 150 N. The hardness of the tablet can be from about 30, 40, or 50 N to about 70, 80, 90 or 100 N.
The oral tablet may include one or more excipients, such as those mentioned above including, but not limited to, ?avoring agents, lubricants, binders, preservatives, and disintegrants.
In another embodiment, the solid dosage form comprises granules of the solid carrier, lipophilic compound in the vehicle, and optionally other excipients. The granules may, for example, be ?lled into a capsule which is administered.
Preparation of the Solid Oral Dosage Forms The solid oral dosage forms bed herein may be formed by (i) preparation of the solid carrier, (ii) preparation of the vehicle, (iii) ing the vehicle into the solid carrier and ?lling the e into capsules.
In one embodiment, s of the t invention are prepared by (ix) preparation of the solid carrier, (iix) pressing the solid r and optionally disintegrants and/or other tablet excipients into adsorbable tablets, (iiix) preparation of the vehicle, (ivx) adsorbing the vehicle into the loadable tablets.
In one embodiment, the compound is part of the carrier, in another embodiment the compound is solubilized in the vehicle, and in a third ment the compound is partly in the carrier and partly solubilized in the vehicle.
The nd and vehicle er form a self-emulsifying drug delivery system (SEDDS) or a self-micro emulsifying drug delivery systems (SMEDDS).
Step (ix) may be carried out by mixing binder or spraying binder solution onto granules of the porous excipient, granulate the mixture in a high shear mixer and drying the granules to provide the granulate.
The carrier granulate may be mixed With tablet excipients, e.g. disintegrants, lubricants etc. and ally the drug derivative and pressed into tablets.
Preparation of the vehicle is done my simply mixing the components and optionally the lipophilic compound until a clear solution appears.
Adsorption is med by immersing the tablet into the vehicle in a surplus of the compound, the time period for adsorbing the drug derivative is controlled and may range from about 30 minutes to about 5 hours, such as from about 30 minutes to about 1 hour. Adsorption can also be achieved by pouring the calculated oil mixture onto a bed of tablets, e. g., rotating in some form of a drum In all of the methods above, the granulate comprising an adsorbent excipient and a release enhancing agent may be ted, such as compressed or molded into a tablet that has a suitable hardness, such as a hardness of about 20 N or more, about 25 N or more, about 30 N or more, about 35 N or more, about 40 N or more, about 45 N or more, about 50 N or more, about 60 N or more, about 70 N or more, about 90 N or more, about 100 N or more. In one embodiment, the ss of the tablet is from about 30 N to about 150 N, such as from about 30 N to about 100 N.
De?nitions The term "no food effect" and "absence of food effect" on oral bioavailability refers to When the 90 percent CI for the ratio of tion geometric means between fed and fasted treatments, based on log- ormed data, is contained in the equivalence limits of 80-125 percent for AUCO-inf (AUCO-t When appropriate) and Cmax.
The term "fasted state" refers to a state of the subject, such as mammal or human, in Which the only lipids, if any, present in the intestine of the subject, apart from any which may have been included in a formulation according to the invention, are endogenous . A reference to the oral administration of a drug or formulation according to the invention to a subject "in the fasted state" is a reference to the oral 2O administration into the digestive system of the subject such that during the uptake into the tic system of a eutically effective amount of the drug, the subject is in the fasted state. This generally means that the subject has not taken a meal at least 3 to 4 hours prior to the administration and, depending on the rate of uptake and the ef?cacy of the drug, no food is taken from 1 to 6 hours after the meal.
The term "fed state" as used herein refers to any state of the subject other than a "fasted state" as described above.
The term "log P" refers to the partition coef?cient of a substance. The log P of a nce is the base ten logarithm of the ratio of solubility of the substance in n-octanol to solubility of the substance in water.
The term r "HLB value" of a surfactant refers to the Hydrophilic-Lipophilic e and is a measure of the degree to which it is hydrophilic or lipophilic, determined by calculating values for the different regions of the molecule. For non—ionic surfactants the HLB=20*Mh/M, Where M is the molecular mass of the Whole molecule and Mh is the molecular mass of the hydrophilic portion of the Molecule. An HLB value of 0 corresponds to a completely lipophilic/hydrophobic molecule, and a value of 20 corresponds to a completely hydrophilic/lipophobic molecule. HLB values 2 10 describes a hydrophilic surfactant.
The term "production of endogenous lipid" as used herein refers to the biosynthesis within the inal tive cells of lipids, including mono, di or triglycerides and phospholipids, from bio- precursors, which bio-precursors could themselves be lipids or lipid conjugates, such as glycerides. For example the biosynthesis may involve the conversion of a lipid species unable to e transport of the drug into the lymphatic transport system into a species which can. The term "production of endogenous lipid" may also refer to the translocation of lipid species into the enterocytes from elsewhere, such that the lipid species, or lipid metabolite thereof, is capable of promoting transport of the drug into the lymphatic transport system.
The term "mammal" or "mammal subject" as used herein (are interchangeable) refers to all sorts of mammals, such as humans, horses, pigs, dogs, cats, sheeps, etc.
All references, including publications, patent ations and patents, cited herein are hereby incorporated by reference to the same extent as if each reference was individually and speci?cally indicated to be incorporated by reference and was set forth in its entirety herein.
All headings and sub-headings are used herein for convenience only and should not be construed as limiting the invention in any way.
Any combination of the described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
Recitation of ranges of values herein are merely intended to serve as a short method of referring dually to each separate value falling within the range, unless other-wise indicated herein, and each separate value is incorporated into the speci?cation as if it were individually recited herein. Unless otherwise , all exact values provided herein are representative of corresponding approximate values (e. g., all exact exemplary values provided with t to a particular factor or measurement can be considered to also provide a ponding approximate measurement, modi?ed by "abou ", where appropriate).
All methods bed herein can be med in any suitable order unless other-wise indicated herein or otherwise y dicted by context.
The terms ca 39 a and "an" and "the" and similar referents as used in the context of de-scribing the ion are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Thus, (G 99 a and "an" and "the" may mean at least one, or one or more.
The use of any and all examples, or ary language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless ise indicated. No language in the speci?cation should be construed as indicating any element is essential to the practice of the invention unless as much is explicitly stated.
The citation and incorporation of patent documents herein is done for convenience only and does not re?ect any View of the validity, patentability and/or enforceability of such patent nts.
The description herein of any aspect or embodiment of the invention using terms such as "comprising", "having", "including" or "containing" with reference to an element or elements is intended to provide support for a similar aspect or ment of the invention that "consists of’, "consists essentially of", or antially comprises" that particular element or ts, unless otherwise stated or clearly contradicted by t (e. g. a composition described herein as comprising a particular element should be understood as also describing a composition consisting of that element, unless otherwise stated or clearly contradicted by context).
This invention includes all modi?cations and equivalents of the subject matter re-cited in the s or claims presented herein to the maximum extent permitted by applicable law.
The es disclosed in the foregoing description may, both separately and in any combination thereof, be material for realizing the invention in diverse forms thereof EXAMPLES Further description of the present invention will now be done by the following miting examples. It should be kept clearly in mind that the examples are merely illustrative of the present ion and should not be construed as limiting the scope of the invention in any way, as many variations and lents that are encompassed by the present invention will become nt to those skilled in the art upon reading the present disclosure.
Example 1: Preparation of Oral SEDDS Formulations for lymphatic targeting Six oral SEDDS formulations were prepared as summarized in Table 1.
Table 1. SEDDS formulations for lymphatic targeting Formulation Summary of Components S1 Olive oil: ol Mono-Oleate 1:3 with Polysorbate 80: Polyoxyl 35 castor oil 1:1, 60% S2 Soybean oil: Glycerol Mono-Oleate 1:1 with Polyoxyl 35 castor oil, 60% fat S3 Soybean oil: Glycerol Mono-Oleate 1:1 with Polyoxyl 35 castor oil, 80% fat S4 Olive oil: Glycerol Mono-Oleate 65:35 with Polysorbate 80: Polyoxyl 35 castor oil 1:1, 60% fat S5 Glycerol Mono-Oleate with yl 35 castor oil, 60% fat S6 Soybean oil: Glycerol Mono—Oleate 1:1 with Polyoxyl 35 castor oil, 70% fat The Six different SEDD systems were ed as shown below in Table 2: Table 2: Placebo SEDDS compositions Ingredient Formulation S1 S2 S3 S4 SS S6 SEDDS Olive oil 9.00 - - 34.4 - - Soybean oil - 54.0 18.0 - — 54.0 Glycerol Mono-Oleate 27.0 54.0 18.0 12.6 36.0 54.0 Polysorbate 80 12.0 - - - - - Polyoxyl 35 castor oil 12.0 72.0 9.0 24.0 24.0 46.3 Total 60.0 180.0 45.0 60.0 60.0 154.3 In each case, the oil components were dispersed and mixed to achieve a clear mono-phasic o vehicle system. Active lipophilic compound is added and dissolved in the placebo SEDD formulations.
Example 2: Solid tablet formulations The Solid Carrier The Solid Carrier was produced by mixing silicon dioxide (Zeofree 5170) with microcrystalline cellulose (Avicel PH 301) or low—substituted hydroxypropyl cellulose (L-HPC LH-21), and then granulate the e with a solution of Maltodextrin (Lycatab DSH) plus adequate amount ofwater in a high shear mixer. After granulation the granules were dried in a ed and sieved.
The carrier composition is given in Table 3.
Table 3: Solid carriers Carrier A Carrier B Carrier C Carrier D Carrier E Carrier F Raw Material Weight Weight Weight mg mg mg % % % /tablet /tablet /tablet 21%;" dl‘mde (ZGO?ee 80.0 75.0 75.0 80.0 60.0 60.0 Microcrystalline cellulose '0 10'0 ' ' ' 10'0 (AvicelPH301) L-HPC LH-21 - - 5.0 5.0 - - Maltodextrin (Lycatab DSH) 15.0 15.0 20.0 15.0 40.0 30.0 Total 100.0 100.0 100.0 100.0 100.0 100.0 Inactive carrier s Solid carrier prepared as described was mixed with 5% to 15% of disintegrant for 10 minutes. Then 0.5% magnesium te was added and mixed for 5 minutes. The mixture was compressed into tablets on a 10x22 mm oval tooling using a Diaf tablet press. The tablet weight was between 800 mg and 1200 mg to ?t the d size and adsorption capacity of the tablets. The tablet composition is given in Table 4. The tablet hardness was 25N to 50 N.
Table 4: Carrier tablets Raw Material Weight % Weight % Weight % Weight % Weight % Weight % Solid carrier A 84.5 Solid carrier B 89.5 Solid carrier C - — Solid carrier D - — - Solid carrier E 89.5 Solid carrier F 84.5 L-HPC LH-1 1 Croscarmellose sodium .0 5.0 (AcDiSol) rystalline cellulose - 10.0 (Avicel PH102) Magnesium stearate 0.50 Total 100% e 3: Solid Oral Dosage Forms All solid dosage forms were prepared to contain 600 mg of long chain lipid. (a) Carrier tablets: Tablet adsorbing was achieved by immersing the carrier tablets in the SEDDS vehicle. 20 tablets of each formulation were sorted to ensure homogeneity, and adsorbed in a 3 liter beaker by ?oating the tablets in an excess of the SEDDS vehicle and allowing the vehicle to be absorbed into the tablet. Adsorption was continued until the desired amount of SEDDS had been ed. (1000 mg SEDDS for 60% fat SEDDS formulations and 750 mg SEDDS for 80% fat SEDDS formulations) (b) Capsules: The active SEEDS were dispensed into an empty gelatin capsule shell by a pipette and the capsules were .
Example 4: Carrier tablet formulations The Solid Carrier The Solid Carrier was produced by mixing Colloidal Silicon dioxide (Aeroperl 300) with 10% microcrystalline cellulose (Avicel PH 101) and 5% Hypromellose ose 90SH—100SR), and then granulate the mixture with a solution of 5% Hypromellose (Metolose 90SH—100SR) plus te amount of water in a high shear mixer. After granulation the granules were dried in a ?uid-bed and sieved.
In the case that an antioxidant is needed to ize the active ingredient to be adsorbed, the antioxidant was added (as a 0.2% solution in ethanol) to the binder solution before it was added to the granulation.
The carrier ition is given in Table 5.
Table 5: Solid carriers Carrier G Carrier H Carrier 1 Carrier J RaW Mat6rial Weight % Weight % Weight % Weight % Silicon dioxide (Aeroperl 300) 80.0 70.0 69.95 69.95 Microcrystalline cellulose (Avicel PH101) 10.0 20.0 20.0 20.0 Hypromellose ose 9OSH-100SR) 10.0 10.0 10.0 10.0 yl almitate — - 0.05 Butylated hydroxytoluoene 0.05 Total 100.0 100.0 100.0 100.0 r tablets Solid carrier prepared as described was mixed Microcrystalline cellulose and/or with 2%-5% of croscaimellose sodium for 10 minutes. Then 0.5% magnesium stearate was added and mixed for 5 minutes.
W0 93380 The mixture was compressed into tablets on a 10x22 mm oval g using a Diaf tablet press. The tablet composition is given in Table 6. The tablet hardness was 34N.
Table 6: Carrier tablet compositions Raw Material Weight % Weight % Weight % Weight % Solid carrier G 70.0 - - Solid carrier H — 97.5 - - Solid carrier I — — 70.0 - Solid carrier J - - - 97.5 Microcrystalline ose 24‘5 ' 24‘5 ' (Avicel PH102) Croscarmellose sodium .0 2.0 5.0 2.0 (Ac-Di-Sol) Magnesium stearate 0.5 0.5 0.5 0.5 Total 100% 100% 100% 100% The carrier tablets were loaded with SEDDS as described in Example 3.
Example 5: Tablets containing an active ingredient The Active Solid Carrier Active solid carrier is prepared by dissolving Abiraterone Acetate in SEDDS 82 (see Table 9) (5% concentration), mixing Silicon dioxide (Zeofree 5170) with 40% maltodextrin (Lycatab DSH) and moistening the mixture with the erone Acetate solution and adequate amount of water in a high shear mixer. After ation the granules are dried on trays and sieved.
The carrier composition is given in Table 7.
Table 7: Solid carriers Raw Material | Active Solid carrier Weight % mg / tablet Silicon dioxide (Zeofree 5170) 54.8 526.2 Maltodextrin (Lycatab DSH) | 36.5 350.8 Abiraterone Acetate | 0.4 4.0 SEDDS 82 | 8.3 80.0 Total 100.0 961.0 Tablets containing Abiraterone Acetate For full amount of Abiraterone e in loadable core tablet: Solid r E prepared as described in Example 2 was mixed with 2% of croscarmellose sodium and Abiraterone Acetate for 10 minutes. Then 0.5% magnesium stearate was added and mixed for 5 minutes. The mixture was ssed into tablets on a 10x22 mm oval tooling using a Diaf tablet press.
For l amount of Abiraterone Acetate in loadable core tablet: Active Solid carrier prepared as described was mixed with 2% of croscarmellose sodium for 10 minutes. Then 0.5% magnesium stearate was added and mixed for 5 minutes. The e was compressed into tablets on a 10x22 mm oval tooling using a Diaf tablet press.
Table 8: Loadable tablets Raw Material Abiraterone Acetate Abiraterone Acetate fully in tablet core partly in tablet core Weight % mg / tablet Weight % mg / tablet Solid carrier granulate 93.40 877.0 Active Solid carrier 97.77 961.0 granulate Croscarmellose 1.87 17.54 1.78 17.54 (Ac-Di-Sol) Abiraterone Acetate 4.26 40.00 Magnesium stearate 0.47 4.39 0.45 4.39 Total 100% 938.9 100% 982.9 SEDDS Vehicles Two SEDDS es (S2 and S2A) are prepared to be adsorbed into the carrier tablets, as shown below in Table 9: Table 9: SEDDS formulations Ingredient S2 S2A Olive oil Soybean oil 18.0 18.0 Glycerol Mono-Oleate 18.0 18.0 Polysorbate 80 Polyoxyl 35 castor oil 24.0 24.0 Abiraterone Acetate - 1.60 Total 60.0 61.60 API cone. in SEDDS - 3.85% In each case, the oil components were sed and mixed to afford a clear mono-phasic placebo vehicle system. For the S2A vehicle, Abiraterone Acetate was dispersed and dissolved into the vehicle system overnight.
Solid Oral Dosage Form All solid dosage forms were prepared to contain 40 mg of Abiraterone Acetate and 600 mg of long chain lipid. The solid dosage forms were prepared as follows Loadable tablets: Tablet adsorption was achieved by immersing the loadable s in the SEDDS vehicle. 20 tablets of each formulation were sorted to ensure homogeneity, and adsorbed in a 3 liter beaker by ?oating the tablets in an excess of the SEDDS vehicle and allowing the vehicle to be ed into the tablet.
Table 10: Active Solid Oral Dosage Forms Ingredient Formulation per solid dosage form A1 A2 Active SEDDS S2A 956 mg Inactive SEDDS S2 1000 mg Partly active loadable tablets 1 tablet Active loadable tablets 1 tablet Example 6: ity study of silicon dioxide compared to a magnesium aluminometasilicate In double experiments, 1 ml of n oil based SEEDS (corresponding to S2 in Example 1) containing 40 mg Testosterone Undecanoate was added to samples of either magnesium aluminometasilicate (Neusilin NS2N granules) or silicon dioxide. The samples were placed at 40°C/75RH in closed glass vial for 1 month in a stability chamber. Following stability storage, the samples were dissolved in 3 mL heptane, following 3 mL anol and taken to 25mL with methanol. The samples were analyzed by HPLC using a Kinetex C18 column (50x4,6 mm) 5nm,column ature 30 °C, mobile phase: 5% water in methanol, ?ow 1,5 ml/min at a wavelength 260 nm. The tograms showed two (2) testosterone undecanoate related impurities that were signi?cantly more abundant in the magnesium aluminometasilicate compared to the n dioxide.
Table 11: Testosterone related impurities after storage at 40°C/75RH after 1 month oftwo (2) different tablet ents silicon dioxide and magnesium aluminometasilicate.
Impurity Impurity RT 3.75 RT 3.95 SEEDS in Silicon dioxide. Sam le no 1. 0.29 0.,15 SEEDS in Silicon dioxide. Samples no. 2 0.39 0.19 Average (n=2) 0.34 0.17 SEEDS in Magnesium iometasilicate. Sample no. 1. 1.39 1.35 SEEDS in Magnesium aluminiometasilicate. Sample no. 2. 1.37 1.34 Average (n=2) 1.38 1.35 Example 7: Tablets containing Abiraterone e The Solid Carrier was produced by mixing Colloidal Silicon dioxide (Aeroperl 300) with Butylated hydroxytoluene and then granulate the e with a solution of 12.5% Maltodextrin (Lycatab DSH) plus adequate amount of water in a high shear mixer. After granulation the granules were dried in a ?uid-bed and . Batch size was 700 g for a 6 L high shear mixer.
The carrier composition is given in Table 7.
Table 12: Solid carrier K Raw Material Solid carrier K Weight % Silicon dioxide (Aeroperl 300) ‘ 79.9 Maltodextrin (Lycatab DSH) | 20.0 Butylated hydroxytoluene I 0.1 Puri?ed water I qs Total | 100.0 Carrier tablets Solid carrier prepared as described was mixed with L-HPC LH11 for 10 minutes. Then 0.5% ium stearate was added and mixed for 5 minutes. The mixture was compressed into tablets on a 10x22 mm oval tooling using a Diaf tablet press. The tablet composition is given in Table 6. The tablet weight was approx. 850 mg and hardness was 3ON.
Table 13: r tablet compositions Raw Material Weight % Solid carrier K 94.5 L—HPC LH11 5.0 Magnesium stearate 0.5 Total 100% SEDDS Vehicle SEDDS vehicle was prepared to be adsorbed into the carrier tablets, as shown below in Table 9: Table 14: SEDDS formulations Ingredient Soybean oil 18.0 Glycerol Mono-Oleate 18.0 Polyoxyl 35 castor oil 24.0 Abiraterone Acetate 1.025 Total 61.0 API conc. in SEDDS 2.5% In each case, the oil components were dispersed and mixed to afford a clear mono-phasic placebo vehicle system. Then Abiraterone Acetate was dispersed and dissolved into the vehicle system overnight.
Solid Oral Dosage Form All solid dosage forms were prepared to contain 16.7 mg of Abiraterone Acetate and 400 mg of long chain lipid. The solid dosage forms were prepared as follows: Loadable s: Tablet adsorption was achieved by immersing the loadable tablets in the SEDDS vehicle. 20 tablets of each formulation were sorted to ensure neity, and adsorbed in a 3 liter beaker by ?oating the tablets in an excess of the SEDDS vehicle and allowing the vehicle to be absorbed into the tablet.
Capsules: Capsules were ?lled with SEDDS on by a pipette.
Table 15: Active Solid Oral Dosage Forms Ingredient Formulation per solid dosage form A3 A4 Active SEDDS S2A 683 mg 683 mg Inactive loadable tablets 1 tablet Hard shell gelatin capsule 1 capsule Example 8: Stability study on effect of additives using silicon dioxide Using the above formulation of silicon dioxide, soybean oil based SEDDS and terone undecnoate, it was igated to stabilize the system further by addition of antioxidants (alpha-tocopherol, yl palmitate) and/or metal ger (EDTA). 0.1% EDTA disodium salt was dissolved in the granulation ?uid and added to the carrier (Carrier K, table 5) and thereby to the carrier tablet (table 6). 0.02% alpha-Tocopherol and 0.025% yl palmitate were dissolved in the SEDDS along with 40 mg Testosterone Undecanoate/1000 mg SEDDS sponding to S2 in Example 1). The samples were placed at 30°C/65RH in closed HdPE containers for 2 month in a stability chamber. Following stability storage, the s were analyzed as described in example 6 by HPLC and for peroxides according to Ph.Eur.
Table 16: Stability effect of additives using n dioxide.
Impurity Impurity Peroxi RRT 0.53 RRT 0.59 de value SEEDS in n dioxide. No antioxidants 0.47 0.47 45.3 SEEDS in Silicon dioxide. EDTA 0,1%, Tocopherol 0,02% 0.04 0.04 1.9 SEEDS in Silicon dioxide. EDTA 0,1%, Tocopherol 0,02% Ascorbyl 0.04 0.05 1.3 palmitate 0,025% SEEDS in n dioxide. Tocopherol 0,04% Ascorbyl palmitate 0.14 0.12 29.2 0,025% SEEDS in Silicon e. Tocopherol 0,02% Ascorbyl ate 0.13 0.09 28.6 0,05% Example 9: Synthesis of C11-paclitaxel and DHA—paclitaxel 700 mg paclitaxel is dissolved in 500 ml dichloromethane. This solution is added 100 mg dimethylaminopyridine and 210 mg Diisopropylcarbodiimide. The solution is stirred and ?ushed With inert gas like nitrogen or argon. To the solution is added either 186 mg undecanoic acid or 328 mg docosahexaene acid and the solution is stirred under inert gas for 1 hour. The reaction mixture is then concentrated to 2-5 ml and applied a 30g silica column for chromatographic puri?cation using a 1:1 mixture of hexane and ethylacetate as eluent. Fractions of each approx. 5 ml eluate is collected and analyzed by HPLC for content of the esteri?ed t. ons with high content of the reaction product is pooled and evaporated to dryness under inert air. The isolated products are immediately dissolved in SEDDs and kept under inert here until ?lled into capsules. Each capsule ns the derivative of paclitaxel in an amount corresponding to 10 or 12.5 mg of the parent compound i.e. paclitaxel. The products are used for the pharmacokinetic study in Beagle dogs as described in example 12.
Example 10: Single Dose Pharmacokinetic Study in Beagle Dogs in the Fasted State of C1 l—paclitaxel and DHA-paclitaxel The study is a randomized, balanced, single dose, cross-over study in Beagle dogs ing pharmacokinetics in fasted state to demonstrate an increased bioavailability, reduced variation in absorption of the C1 1-paclitaxel and DHA—paclitaxel.
The clitaxel and DHA—paclitaxel products prepared as described in example 9 is compared with an oral solution of the infusion concentrate of paclitaxel being the comparator. The total oral dosage provided is 75 mg calculated as parent compound.
The dogs are deprived of food from late on the day prior dosing. Pentagastrin is dosed via IM (6 pig/kg, 200 ug/mL in water) 30 min prior to administration. Pentagastrin is administered to ensure low pH in the dog’s stomach, which otherwise will not have an as low pH as in humans stomachs. Gastric pH is measured right before pentagastrin dosing and right before dosing of the erone acetate formulations.
The capsule is put ly on the aditus laryngis of the dog to ensure that the tablet is not chewed but swallowed whole. The dogs receive totally 100 ml of water immediately ing the dosing.
Blood samples (approximately No.5 mL) are taken from each animal at each dosing occasion on 10 time points up to 24 hours after dosing including a pre-dose.
The pharmacokinetic parameters calculated are i.e. total exposure, or area under the concentration- time curve (AUCO-inf, AUCO-t), peak exposure (Cmax), and time to peak exposure (Tmax).
Example 11: Single Dose Pharmacokinetic Study in Beagle Dogs in the Fasted and Fed State of tablet containing abiraterone acetate in SEDDS The study is a randomized, balanced, single dose, cross-over study in Beagle dogs comparing pharmacokinetics in fasted and fed state, respectively to trate an increased bioavailability, reduced variation in absorption well as a reduced or no food effect of the tablet with abiraterone acetate in the SEDDS.
A tablet containing Abiraterone acetate in SEDDS is compared to Zytiga® tablets (comparator product). Dogs receive a single dose of each product. In fasted state the dogs are ed of food from late afternoon the day prior dosing. The dogs are fed 5 minutes prior to dosing in the fed state part of the study.
Pentagastrin is dosed via IM (6 ug/kg, 200 ug/mL in water) 30 min prior to administration.
Pentagastrin is stered to ensure low pH in the dog’s stomach, which otherwise will not have an as low pH as in humans stomachs. Gastric pH is measured right before pentagastrin dosing and right before dosing of the abiraterone acetate formulations.
The tablet is put directly on the aditus laryngis of the dog to ensure that the tablet is not chewed but wed whole. To ensure the complete oral dose is ed, the dogs receive 100 mL of water immediately following the tablet dosing.
Blood samples (approximately No.5 mL) are taken from each animal at each dosing occasion on 10 time points up to 24 hours after dosing including a pre—dose.
The pharmacokinetic parameters calculated are i.e. total exposure, or area under the concentration- time curve (AUCO-inf, AUCO-t), peak exposure (Cmax), and time to peak exposure (Tmax). The variation in absorption is calculated and compared to that of Zytiga in both fed and fasted state.
Example 12: Single Dose cokinetic Study in Beagle Dogs in the Fasted State of C1 l-paclitaxel and DHA-paclitaxel administered in SEDDS formulation S2 in a capsule The study was a randomized, balanced, single dose, parallel group study in Beagle dogs comparing pharmacokinetics in fasted state of capsules containing C1 1-paclitaxel and DHA—paclitaxel, respectively in SEDDS formulation S2 (see Table 1).
The C1 l-paclitaxel and DHA—paclitaxel products were ed as described in example 8 and were compared to an oral solution 2 mg/ml of the infusion concentrate of paclitaxel being the comparator. The strength of each capsule was 12.5 mg of paclitaxel equivalents for the C-11 paclitaxel capsule and 10 mg of paclitaxel ewquivalents for the DHA-paclitaxel. The total oral dosage provided was 75 mg calculated as parent compound for paclitaxel and C1 l-paclitaxel, respectively and 60 mg calculated as parent compound for DHA—paclitaxel.
The dogs were deprived of food from late afternoon the day prior dosing. The capsule was put ly on the aditus laryngis of the dog to ensure that the capsule is not chewed but swallowed whole. All dogs received totally 100 ml of water immediately ing the dosing.
Blood samples (approximately ~0.5 mL) were taken from each animal at each dosing occasion on 10 time points up to 24 hours after dosing ing a se.
The pharrnacokinetic parameters calculated are i.e. total exposure, or area under the concentration- time curve (AUCO-inf, AUCO-t), peak exposure (Cmax), time to peak exposure (Tmax), terminal half-life tl/z and the sion rate from prodrug to parent.
Table 17: Summary of major acokinetic parameters of pro-drug or parent after oral dose at 75 mg paclitaxel equivalents/animal (paclitaxel and paclitaxel undecanoate) or 60 mg paclitaxel equivalents/animal (paclitaxel—DHA) in male beagle dogs (N=4).
PK parameters Cmax Tm." tl/z AUCM AUCMO Unit ng/mL hr hr hr*ng/mL mL Treatment Group PK parameters of prodrug "11:33:32; 422 a) 2.00 6.44 1778 b) 1882 °> Paclitaxel-DHA 63.8 d) 4.50 6.33 402 e) 643 0 axel undecanoate: a) Equivalent 1’) Equivalent C) Equivalent to 352 ng/mL of paclitaxel; to 1485 hr*ng/mL of paclitaxel; to 1572 hr’ng/mL of paclitaxel Paclitaxel-DHA: d) Equivalent to 46.8 ng/mL of paclitaxel; e) Equivalent to 295 hr*ng/mL of axel; f) Equivalent to 471 hr’ng/mL of paclitaxel (parent) / PK parameters Cmax Tmax t1/ A 2 UC"'t AUC"'00 AUC0_t(pr0drug) Unit ng/mL hr hr hr*ng/mL hr*ng/mL % Treatment Group PK parameters of paclitaxel Paclitaxel 148 2.50 13.7 771 973 NA "53:11:33; 2.26 8.00 19.6 24.3 52.0 1.48 axel—DHA 10.4 2.25 11.6 73.3 97.2 22.3 Example 13: Single Dose Pharmacokinetic Study in Beagle Dogs in the Fasted and Fed State of a tablet and a capsule containing Abiraterone acetate in SEDDS formulation S2 The study was a randomized, balanced, single dose, cross-over study in Beagle dogs comparing pharmacokinetics in fasted and fed state, tively to demonstrate low variation in absorption well as a reduced or no food effect of the tablet and capsule, respectively containing abiraterone acetate in a SEDDS formulation S2 (see Table 1).
Dogs received 6 es or tablet of 16.7 mg corresponding to 100 mg of abiraterone acetate as a single dose. In fasted state the dogs were deprived of food from late afternoon the day prior dosing. The dogs were fed 30 minutes prior to dosing in the fed state part of the study.
Pentagastrin was dosed via IM (6 ug/kg, 200 ug/mL in water) 30 min prior to administration.
Pentagastrin is administered to ensure low pH in the dog’s stomach, which ise will not have an as low pH as in humans stomachs. Gastric pH was measured right before pentagastrin dosing and right before dosing of the abiraterone acetate ations.
The tablets or capsules were put directly on the aditus laryngis of the dog to ensure that the products were not chewed but swallowed whole. To ensure the te oral dose is received, the dogs received 100 mL of water immediately following the dosing.
Blood s (approximately No.5 mL) were taken from each animal at each dosing occasion on 10 time points up to 24 hours after dosing including a pre-dose.
The pharmacokinetic ters calculated are i.e. total exposure, or area under the concentration- time curve (AUCO-inf, AUCO-t), peak exposure (Cmax), time to peak exposure (Tmax) and terminal half-life "/2. The variation in absorption was calculated in both fed and fasted state.
Table 18: Summary ofmajor pharmacokinetic parameters of abiraterone after oral dose of abiraterone acetate at 100 mg/animal (N=4/time point) in fasted state and with food.
PK parameters Cmax Tmax ty, AUCH AUCM, Unit ng/mL hr hr hr*ng/mL hr*ng/mL Treatment Group PK parameters of erone Tablet-fasted 38.0 2.63 3.83 193 202 Capsule-fasted 440 1.25 4.34 1218 1233 Tablet-fed 20.4 3.63 1.37 74.9 98.9 Capsule—fed 541 1.13 3.68 1132 1138 The CV% for me, AUC0_t and AUCM for the capsules were 23.4%, 10.4% and 10.5% in fasted state and 33.6%, 19.3% and 19.2 % in fed state, respectively.
The CV% for Cmax, AUC0_I and AUCOm for the s were 21.7%, 16.1% and 16.6% in fasted state and 45.0%, 43.2% and 10.0 % in fed state, respectively. e 14: sis of Docosahexaenoic acid amide of octreotide 400 mg octreotide and 45 mg dimethylaminopyridine is dissolved in 7 ml DMF. 200ul diisopropylcarbodiimide is added. 163 mg sanoic acid is dissolved in 9 ml chloroform slightly heated. The solutions are mixed and stirred for 1 hour. The reaction mixture is concentrated and transferred to a 15g silicondioxide for column chromatography using hexane/ethylacetate 1/1. The product was further puri?ed by ?ltering through a 3g silicondioxide column with hexane/ethylacetate 1/1 and the eluate is collected and concentrated to dryness. The total yield is 440 mg octreotide ceroate corresponding to approx. 80% overall yield.

Claims (24)

We claim:
1. A solid oral dosage form composition comprising a lipophilic compound having a log P of at least 5, and a vehicle, wherein the vehicle comprises (a) a fat component in an amount of at least 700 mg sufficient to achieve lymphatic absorption in a , wherein the fat component is ed from a mono- and a triglyceride of long chain fatty acids, wherein the long chain fatty acids in the monoglycerides are selected from fatty acid chains having from 14 to 24 carbon atoms and the long chain fatty acids in the triglycerides are selected from fatty acid chains having from 14 to 24 carbon atoms, wherein the weight ratio of triglycerides to monoglycerides is in a range from 2.8:1 to 1:5, and (b) a hydrophilic surfactant wherein the weight ratio (a):(b) is from 10:1 to 1:2.
2. The composition of claim 1 wherein the fat component comprises a monoglyceride and a triglyceride of long chain fatty acids, wherein the weight ratio of triglycerides to monoglycerides is in a range from 2:1 to
3. The composition of any one of the preceding claims n ition exhibits an AUC(0-inf) (fasted) / AUC(0-inf) (fed)) of at least 0.8.
4. The composition of any one of the preceding claims wherein the weight ratio of (a):(b) ranges from 4:1 to
5. The composition of any one of the preceding claims wherein the long chain fatty acids in the ycerides are selected from linolenic acid, oleic acid, palmitic acid, linoleic acid, or stearic acid.
6. The composition of any one of the preceding claims 1-5 wherein the long chain fatty acids in the triglycerides are selected from linolenic acid, oleic acid, palmitic acid, linoleic acid, or stearic acid.
7. The composition of any one of the preceding claims 1-6 wherein the fat component comprising a triglyceride of long chain fatty acids is selected from a naturally derived oil.
8. The composition of claim 7 n the lly derived oil is ed from soybean oil, olive oil, sesame oil, safflower oil, peanut oil, rapeseed oil, sunflower oil, coconut oil, corn oil, sunflower seed oil, cotton seed oil, palm oil, arachidis oil or any combination thereof.
9. The composition of any one of the preceding , wherein the fat component is selected from olive oil, soybean oil, mixtures of olive oil and glycerol mono oleate, and mixtures of n oil and glycerol mono oleate.
10. The composition of any one of the preceding , wherein the vehicle is self-emulsifying.
11. The ition of any one of the preceding claims, wherein the composition, upon dilution in ed water, forms droplets which have a d50 of less than 200 eter.
12. The composition of any one of the preceding claims, wherein the composition, upon dilution in purified water, forms droplets which have a d50 of less than 40 micrometer.
13. The composition of any one of the preceding claims, wherein the composition, upon dilution in purified water, forms droplets which have a d50 of less than 20 micrometer.
14. The composition of any one of the preceding claims, wherein the composition, upon dilution in purified water, forms droplets which have a d50 of less than 10 micrometer.
15. The composition of any one of the preceding claims, wherein the ition, upon on in purified water, forms droplets which have a d50 of less than 5 micrometer.
16. The composition of claim 1 being selected from a granule, a capsule or tablet.
17. The composition of any one of the preceding claims wherein the hydrophilic surfactant is ed from hydrogenated castor oil ethoxylates, polysorbates or any other hydrophilic surfactant with a Hydrophile- Lipophile Balance (HLB) value of 10 or higher, and any combination thereof.
18. The composition of any one of the preceding claims wherein the lipophilic compound is selected from abiraterone acetate, acitretin, strenol, alpha tocopherol, amidarone, aprepitant, atorvastatin, tene, bromocriptine, candesartan, cinacalcet, clomiphene, diethyl stilbestrol, dihomo-gamma- ic acid, ebastine, ergocalciferol, fenofibrate, fucidic acid, halofantrine, irbesartan, isotretinoin, itraconazole, lapatinib, liraglutide, loratidine, lone decanoate, nelfinavir, olmesartan, orlistat, posaconazole, probucol, raloxifene, ritonavir, tamoxifen, telmisartan, teprenone, tipranavir, valsartan, and zuclopenthixol.
19. The composition of any one of the preceding claims wherein the lipophilic compound is selected from a compound which has been modified by ment of a lipophilic moiety to increase the lipophilicity of the ilic compound to at least log P of at least 5 making it suitable for lymphatic uptake.
20. The composition of claim 19 n the lipophilic compound is selected from a paclitaxel prodrug; octreotide covalently attached to a fatty acid with at least 20 carbon atoms in an amide formation; leuprolide covalently attached to a fatty acid ester via the aliphatic or aromatic hydroxyl group present in the peptide; and propofol covalently attached to a fatty acid ester via the phenolic aromatic hydroxy group.
21. The paclitaxel prodrug of claim 20, wherein the paclitaxel prodrug is paclitaxel docosahexaenoate.
22. The paclitaxel prodrug of claim 20, wherein the paclitaxel prodrug is axel undecanoate.
23. The paclitaxel g of claim 20, n the paclitaxel prodrug is paclitaxel oleate.
24. The paclitaxel prodrug of claim 20, wherein the paclitaxel prodrug is axel stearate.
NZ728110A 2015-06-17 Solid oral dosage form of lipophilic compounds NZ728110B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14173067 2014-06-19
PCT/EP2015/063606 WO2015193380A2 (en) 2014-06-19 2015-06-17 Solid oral dosage form of lipophilic compounds

Publications (2)

Publication Number Publication Date
NZ728110A NZ728110A (en) 2023-09-29
NZ728110B2 true NZ728110B2 (en) 2024-01-09

Family

ID=

Similar Documents

Publication Publication Date Title
CA2948225C (en) Solid oral dosage form of lipophilic compounds
RU2228201C2 (en) Oral galenics with rapid release and sustained-release comprising absorption-enhancing agent and application of this absorption-enhancing agent
CZ64193A3 (en) Two-phase agent for releasing lipophilic medicaments, and process for preparing thereof
CN111757729A (en) Modified release compositions comprising cannabinoids
US20100086592A1 (en) Modified dosage forms of tacrolimus
US20190388434A1 (en) (17-ß)-3-Oxoandrost-4-En-17-Yl Undecanoate Compositions and Methods of Their Preparation and Use
EP2934591B1 (en) Solid oral dosage form of testosterone derivative
JP2019501199A (en) Proliposome testosterone undecanoate formulation
WO2008083561A1 (en) Oral pharmaceutical composition of glycyrrhizin or its salts and the preparation method thereof
KR101821441B1 (en) Formulations of 14-epi-analogues of vitamin d
NZ728110B2 (en) Solid oral dosage form of lipophilic compounds
CN114099518B (en) Oral fulvestrant pharmaceutical composition and preparation method thereof
CN115804753A (en) Agomelatine self-microemulsion composition, capsule and application thereof
JP2004518679A (en) Pharmaceutical composition comprising sampatrilatate dispersed in a lipoid vehicle
AU2019314397A1 (en) Solid oral formulations of amphotericin B
JPS6062960A (en) Gelatine soft capsule containing vatamin a,e